Oxford BioMedica and Axovant Worldwide Exclusive Licence Agreement for OXB-102 for Parkinson’s diseaseExclusive Licence Agreement • June 5th, 2018
Contract Type FiledJune 5th, 2018This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares (the “Securities”). Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, the contents of this presentation have not been formally verified by Oxford BioMedica plc (the “Company”) or any other person. Accordingly, no representation or warranty, expressed or implied,